Genetic Medicines Co. Reveals Transformative 'Only-of-Its-Kind' AAV Therapy Milestone
Company Wins Back Promising Eye Disease Drug and Eyes Two Product Launches by 2028
Research Report
Massachussetts Biotech Co. Faces Major Melanoma Drug Setback
Biotech Firm Advances Voice-Based Intoxication Tech Aiming to Revolutionize Medical Diagnostics
MA Biotech Co. Downgraded to Sell After Second FDA CRL for RP-1 Melanoma BLA
Research Report
What Do Analysts Think About the Biopharma Set on Transforming Psychiatry
Canadian Biotech Co. Appoints Elite Regulatory Expert for Chile Expansion
California Biotech Co. Advances Depression Drug Breakthrough
Alto Neuroscience Inc. (ANRO:NYSE) pivots after mixed trial results, targeting treatment-resistant depression with analyst support and major market growth potential.San Francisco Pharma Co.'s HORIZON Phase 2 Data Validates APOL1 Path to Pivotal Trial
Research Report
H.C. Wainwright reiterated its rating and price target on Maze Therapeutics (MAZE:NASDAQ), following KOL calls that validated the HORIZON Phase 2 dataset as biologically coherent, confirmed the diabetic cohort signal as drug-attributable proof of concept, and outlined a clear path to pivotal trials. Name Change, Share Consolidation, and US Clinic Strategy Signal Shift Toward Alzheimer's Diagnostics
Algernon Health (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) plans to rebrand to Grey Matters Health Inc. while advancing its Alzheimer's diagnostic strategy and U.S. clinic rollout.Philly Biotech Co. Develops High-Potential Autoimmune Therapy Breakthrough
Cabaletta Bio Inc. (CABA:NASDAQ) pushes rese-cel CAR T program forward with strong clinical momentum, production scalability, and analyst-backed upside potential.The World's First AI Voice Detection For Drugs & Alcohol With Charts That Beckon Investors To Buy
Contributed Technical Analyst Opinion
Technical Analyst Stewart Thomson explains why he thinks MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) is a Speculative Buy. Biotech Company Uncovers Breakthrough Canine Arthritis Treatment
Israeli co. Can-Fite BioPharma Ltd. (CANF:NYSEAmerican) teamed up with Vetbiolix to trial Piclidenoson for dogs, with Phase 2 results due Q3 2026. Yet, one analyst still rates the stock as a Hold. Read on to see why.Biotech Price Target Raised on Strong FSHD and DM1 siRNA Data
Research Report
Wedbush Securities raised its price target on Sarepta Therapeutics Inc. (SRPT:NASDAQ), following promising Phase 1/2 data for siRNA candidates SRP-1001 in FSHD and SRP-1003 in DM1, citing superior muscle concentration and a clean safety profile versus rival programs from Novartis and Dyne Therapeutics. 
Streetwise Key Charts
